CDC Plans Massive COVID-19 Antibody Study to Understand Spread of SARS-CoV-2 Virus
By HospiMedica International staff writers Posted on 20 May 2020 |
Illustration
In order to learn more about how many people have been infected with SARS-CoV-2 and how it is spreading through the US population, the US Centers for Disease Control and Prevention {(CDC) Atlanta, GA, USA} plans to conduct a huge national serology test.
Investigations using serology testing are called seroprevalence surveys. CDC is collaborating with public health and private partners on a variety of seroprevalence surveys of different sizes, locations, populations studied, and purposes. According to a Reuters report ahead of an official announcement, the CDC’s SARS-CoV-2 antibody study will test about 325,000 people across 25 US cities. The CDC will test 1,000 blood donors in each of the 25 selected cities every month for 12 months. After 18 months, it plans to also test the blood of an additional 25,000 volunteers.
CDC has developed a laboratory blood test to assist with efforts to determine how much of the US population has been infected with SARS-CoV-2. CDC’s serologic test is based on a set of serologic tests that it has developed and optimized to detect SARS-CoV-2 antibodies in serum. These tests use live virus (isolated by CDC in February 2020) and a specific SARS-CoV-2 protein, the spike antigen. CDC’s serologic test is designed to detect antibodies produced in response to SARS-CoV-2 and to avoid detection of antibodies against other common coronaviruses that cause less severe illnesses, such as colds. CDC’s test has a specificity of greater than 99% and a sensitivity of 96% based on initial tests. It can be used to identify past SARS-CoV-2 infection in people who were infected at least 1 to 3 weeks previously.
Related Links:
Centers for Disease Control and Prevention (CDC)
Investigations using serology testing are called seroprevalence surveys. CDC is collaborating with public health and private partners on a variety of seroprevalence surveys of different sizes, locations, populations studied, and purposes. According to a Reuters report ahead of an official announcement, the CDC’s SARS-CoV-2 antibody study will test about 325,000 people across 25 US cities. The CDC will test 1,000 blood donors in each of the 25 selected cities every month for 12 months. After 18 months, it plans to also test the blood of an additional 25,000 volunteers.
CDC has developed a laboratory blood test to assist with efforts to determine how much of the US population has been infected with SARS-CoV-2. CDC’s serologic test is based on a set of serologic tests that it has developed and optimized to detect SARS-CoV-2 antibodies in serum. These tests use live virus (isolated by CDC in February 2020) and a specific SARS-CoV-2 protein, the spike antigen. CDC’s serologic test is designed to detect antibodies produced in response to SARS-CoV-2 and to avoid detection of antibodies against other common coronaviruses that cause less severe illnesses, such as colds. CDC’s test has a specificity of greater than 99% and a sensitivity of 96% based on initial tests. It can be used to identify past SARS-CoV-2 infection in people who were infected at least 1 to 3 weeks previously.
Related Links:
Centers for Disease Control and Prevention (CDC)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans